GlaxoSmithKline (GSK) has signed a new four-year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The US government is purchasing the medicine as a counter measure against a potential bioterrorist attack. Under the terms of the new contract, GSK will provide 60,000 doses to the US government over four years, at a value of approximately $196 million.
Help employers find you! Check out all the jobs and post your resume.
